Skip to main content
SpringerLink
Log in

Kommentar zur 2013-ESH/ESC-Leitlinie zum Management der arteriellen Hypertonie

Comments on the 2013 ESH/ESC guidelines on management of arterial hypertension

  • Leitlinien
  • Published:
Der Kardiologe Aims and scope

Zusammenfassung

Im Juni 2013 wurden die neuen European Society of Hypertension (ESH)/European Society of Cardiology (ESC)-Leitlinien zum Management der arteriellen Hypertonie publiziert. Die Deutsche Hochdruckliga e.V. DHL®/Deutsche Gesellschaft für Hypertonie und Prävention und die Deutsche Gesellschaft für Kardiologie (DGK) haben sich erstmalig entschlossen, diese Leitlinien in Form praxisnaher Pocketleitlinien gemeinsam zu übersetzen. Die DHL/DGK-Pocketleitlinien sind eine genaue Übersetzung der ESH/ESC-Pocketleitlinien. Mit dem vorliegenden Kommentar, möchten wir über bedeutende Änderungen der neuen Leitlinien gegenüber den vorpublizierten Versionen informieren. Zusätzlich werden unter Berücksichtigung nationaler Rahmenbedingungen und der Bewertung durch DHL/DGK-Expertenkommissionen einzelne kontroverse ESH/ESC-Empfehlungen diskutiert. Insbesondere werden die Bedeutung der Blutdruckmessung außerhalb der Praxis, neue Zielblutdruckwerte, Änderungen in der medikamentösen Therapie und das Vorgehen bei therapieresistenter Hypertonie besprochen. Abschließend werden die Limitationen der aktuellen Leitlinien diskutiert.

Abstract

In June 2013 the European Society of Hypertension (ESH) and European Society of Cardiology (ESC) guidelines for the management of arterial hypertension were published. For the first time the German Hypertension League (DHL®), German Society of Hypertension and Prevention, and the German Society of Cardiology (DGK) decided to translate these guidelines as clinical practice pocket guidelines in a collaborative manner. The DHL/DGK pocket guidelines represent an exact translation of the ESH/ESC pocket guidelines. With the present comments we want to inform clinicians about important changes in the new guidelines. In consideration of the national regulatory environment, and after evaluation by DHL/DGK expert panels, selected controversial ESH/ESC recommendations will be discussed. In particular, the importance of out-of-office blood pressure measurements, new blood pressure targets, changes in antihypertensive drug therapy, and new approaches in resistant hypertension will be reviewed. Finally, the limitations of the current guidelines will be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Mancia G, Fagard R, Narkiewicz K et al (2013) 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 31:1281–1357

    Article  CAS  PubMed  Google Scholar 

  2. Mancia G, Fagard R, Narkiewicz K et al (2013) 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34:2159–2219

    Article  PubMed  Google Scholar 

  3. Lim SS, Vos T, Flaxman AD et al (2012) A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2224–2260

    Article  PubMed  Google Scholar 

  4. Neuhauser H, Thamm M, Ellert U (2013) Blood pressure in Germany 2008–2011: results of the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 56:795–801

    Article  CAS  Google Scholar 

  5. Janhsen K, Strube H, Starker A (2008) Hypertonie. Gesundheitsberichterstattung des Bundes 43:1–35

    Google Scholar 

  6. Bliziotis IA, Destounis A, Stergiou GS (2012) Home versus ambulatory and office blood pressure in predicting target organ damage in hypertension: a systematic review and meta-analysis. J Hypertens 30:1289–1299

    Article  CAS  PubMed  Google Scholar 

  7. Ward AM, Takahashi O, Stevens R, Heneghan C (2012) Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies. J Hypertens 30:449–456

    Article  CAS  PubMed  Google Scholar 

  8. Mancia G, De Backer G, Dominiczak A et al (2007) 2007 Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25:1105–1187

    Article  CAS  PubMed  Google Scholar 

  9. Schrier RW, Estacio RO, Esler A, Mehler P (2002) Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61:1086–1097

    Article  PubMed  Google Scholar 

  10. McMurray JJ, Holman RR, Haffner SM et al (2010) Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 362:1477–1490

    Article  CAS  PubMed  Google Scholar 

  11. Zanchetti A, Grassi G, Mancia G (2009) When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 27:923–934

    Article  CAS  PubMed  Google Scholar 

  12. UKPDS 38 (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 317:703–713

    Article  Google Scholar 

  13. Hansson L, Zanchetti A, Carruthers SG et al (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351:1755–1762

    Article  CAS  PubMed  Google Scholar 

  14. Beckett NS, Peters R, Fletcher AE et al (2008) Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358:1887–1898

    Article  CAS  PubMed  Google Scholar 

  15. Appel LJ, Wright JT, Greene T Jr et al (2010) Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 363:918–929

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Sarnak MJ, Greene T, Wang X et al (2005) The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 142:342–351

    Article  PubMed  Google Scholar 

  17. Upadhyay A, Earley A, Haynes SM, Uhlig K (2011) Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med 154:541–548

    Article  PubMed  Google Scholar 

  18. Law MR, Morris JK, Wald NJ (2009) Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338:b1665

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Roush GC, Holford TR, Guddati AK (2012) Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension 59:1110–1117

    Article  CAS  PubMed  Google Scholar 

  20. Zanchetti A, Mancia G (2012) Longing for clinical excellence: a critical outlook into the NICE recommendations on hypertension management – is nice always good? J Hypertens 30:660–668

    Article  CAS  PubMed  Google Scholar 

  21. Parving HH, Brenner BM, McMurray JJ et al (2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367:2204–2213

    Article  CAS  PubMed  Google Scholar 

  22. Yusuf S, Teo KK, Pogue J et al (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547–1559

    Article  CAS  PubMed  Google Scholar 

  23. Gupta AK, Arshad S, Poulter NR (2010) Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 55:399–407

    Article  CAS  PubMed  Google Scholar 

  24. Bhatt DL, Kandzari DE, O’Neill WW et al (2014) A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370(15):1393–1401

    Article  CAS  PubMed  Google Scholar 

  25. Deutsche Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e.V. (2014) ESC POCKET GUIDELINES. Leitlinien für das Management der arteriellen Hypertonie. Börm Bruckmeier, Grünwald (im Druck)

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. Den Interessenkonflikt der Autoren finden Sie online auf der DGK-Homepage unter http://leitlinien.dgk.org/bei der entsprechenden Publikation. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Center for Cardiovascular Research (CCR), Institut für Pharmakologie, Charité Universitätsmedizin Berlin, Hessische Str. 3–4, 10115, Berlin, Deutschland

    U. Kintscher

  2. Innere Medizin III – Kardiologie, Angiologie und internistische Intensivmedizin, Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes, Homburg Saar, Deutschland

    M. Böhm

  3. Herzzentrum Alter Hof, Hypertension Excellence Center (ESH), München, Deutschland

    F. Goss

  4. Deutsche Hypertonie Akademie (DHL), Heidelberg, Deutschland

    R. Kolloch

  5. Institut für Klinische Pharmakologie und Toxikologie, Charité Universitätsmedizin Berlin, Berlin, Deutschland

    R. Kreutz

  6. Medizinische Klinik 4, Nephrologie und Hypertensiologie, Universitätsklinikum Erlangen, Erlangen, Deutschland

    R. Schmieder

  7. Klinik für Herz- und Kreislauferkrankungen im Erwachsenenalter, Deutsches Herzzentrum München, Technische Universität München; und Deutsches Zentrum für Herz- und Kreislaufforschung (DZHK), Partner Munich Heart Alliance, Lazarettstr. 36, 80636, München, Deutschland

    H. Schunkert

Authors
  1. U. Kintscher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Böhm
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Goss
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Kolloch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Kreutz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Schmieder
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H. Schunkert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to U. Kintscher or H. Schunkert.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kintscher, U., Böhm, M., Goss, F. et al. Kommentar zur 2013-ESH/ESC-Leitlinie zum Management der arteriellen Hypertonie. Kardiologe 8, 223–230 (2014). https://doi.org/10.1007/s12181-014-0575-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12181-014-0575-y

Schlüsselwörter

Keywords

Search

Navigation